4-(2-吡咯烷-1-乙基)-苯胺 | 168897-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-吡咯烷-1-乙基)-苯胺
• 英文名称: 4-(2-pyrrolidin-1-yl-ethyl)phenylamine
• 英文别名: 4-(2-(pyrrolidin-1-yl)ethyl)aniline；4-[2-(pyrrolidin-1-yl)ethyl]aniline；4-(2-pyrrolidlin-1-yl-ethyl)-phenylamine；4-(2-(pyrrolidin-1-yl)ethyl)benzenamine；4-(2-Pyrrolidin-1-yl-ethyl)-phenylamine；4-(2-pyrrolidin-1-yl-ethyl)-aniline；4-(2-pyrrolidin-1-ylethyl)aniline
• CAS: 168897-20-9
• 化学式: C₁₂H₁₈N₂
• mdl: MFCD04114507
• 分子量: 190.288
• InChiKey: WAOKZNBDXFOXSA-UHFFFAOYSA-N

物化性质

• 沸点：
  314.9±17.0 °C(Predicted)
• 密度：
  1.055±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(2-吡咯烷-1-乙基)-苯胺 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  发现了一系列新型的吡啶和嘧啶羧酰胺，它们是Btk的有效和选择性共价抑制剂

  摘要：

  Btk是治疗一系列B细胞恶性肿瘤以及几种自身免疫性疾病（例如鼠科狼疮和类风湿关节炎）的有吸引力的靶标。目前正在开发Btk的几种共价不可逆抑制剂，包括已批准用于治疗B细胞恶性肿瘤的依鲁替尼。在这里，我们描述了我们使用基于X射线导向结构的设计（SBD）来确定共价Btk抑制剂的新型化学系列的努力。所得的吡啶羧酰胺是有效且选择性的Btk抑制剂，具有出色的酶和细胞抑制活性。

  DOI：

  10.1016/j.bmcl.2018.09.033
• 作为产物：
  描述：

  2,2-dibromo-1-(4-nitrophenyl)ethene 在 sodium tetrahydroborate 、 10% palladium on activated charcoal 、 三氟化硼乙醚 、 水 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 4-(2-吡咯烷-1-乙基)-苯胺
  参考文献：
  名称：

  Synthesis and biological evaluation of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

  摘要：

  A series of new 4 beta-anilino-4'-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4 beta position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.016

文献信息

• 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US20140371204A1

  公开（公告）日：2014-12-18

  The invention relates to compounds of Formula (I) wherein ring A, X, (R 1 ) n , R 2 , R 3 , R 4 , R 4′ , R 5 , n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.

  本发明涉及式(I)化合物，其中环A、X、(R1)n、R2、R3、R4、R4′、R5、n和p如描述中所述；涉及药用可接受的盐，以及将此类化合物用作药物，尤其是用作CXCR3受体的调节剂。
• Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
  申请人：HALLEY Frank

  公开号：US20090082379A1

  公开（公告）日：2009-03-26

  Compounds of formula (I): wherein Ra, Rb, R, X 1 and X 2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.

  式(I)的化合物： 其中Ra、Rb、R、X1和X2如所定义，提供了包括所述化合物的药物组合物、制备过程和使用方法。
• Kinase Inhibitors
  申请人：Wurster A. Julie

  公开号：US20070032478A1

  公开（公告）日：2007-02-08

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。
• 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE
  申请人：Player R. Mark

  公开号：US20080114007A1

  公开（公告）日：2008-05-15

  The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R 101 and R 200 are described in the specification.

  本发明针对当前对选择性和强效蛋白酪氨酸激酶抑制剂的需求，提供对c-fms激酶的强效抑制剂。本发明涉及以下式I的新化合物： 或其盐、对映体、互变异构体、结晶、多晶型、无定形、溶剂化物、水合物、酯、前药或代谢物形式，其中A、Y、Z、R 101 和R 200 在说明书中有描述。
• [EN] PYRIMIDINE INHIBITORS OF KINASE ACTIVITY<br/>[FR] INHIBITEURS PYRIMIDINES DE L'ACTIVITÉ KINASE
  申请人：ABBOTT LAB

  公开号：WO2010138576A1

  公开（公告）日：2010-12-02

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

  本发明涉及式(I)的化合物或其药用可接受的盐或溶剂，其中G1、R2、R3、R4、R5、n、p、q、Ar1和Ar2在描述中有定义。本发明还涉及制备所述化合物的方法，以及包含所述化合物的组合物，用于抑制IGF-IR等激酶。